Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFAST.L Share News (FAST)

  • There is currently no data for FAST

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 19th Mar 2014 09:00

Afren: Canaccord Genuity lowers target price from 185p to 180p and stays with its buy recommendation.Antofagasta: Westhouse Securities reduces target price from 1060p to 985p staying with its buy recommendation. Credit Suisse downgrades from neutral to underperform with a target price of 750p. JP Morgan cuts target price from 850p to 830p and stays with its neutral rating. Citi lowers target price from 800p to 760p and keeps its sell recommendation.ASOS: Deutsche Bank reduces target price from 6200p to 5800p retaining a hold recommendation. Citi reduces target price from 8000p to 7000p, while its buy recommendation remains unchanged.Barclays: Deutsche Bank lowers target price from 325p to 320p staying with its buy recommendation. JP Morgan cuts target price from 300p to 285p and maintains an overweight rating.BBA Aviation: Jefferies ups target price from 345p to 385p and retains its buy recommendation.Charlemagne Capital: JP Morgan shifts target price from 15p to 16p leaving its underweight rating unaltered.Consort Medical: Canaccord Genuity upgrades from hold to buy with a target price of 1044p.Daily Mail & General Trust: Westhouse Securities increases target price from 864p to 960p, while leaving its neutral rating unaltered.Eland Oil & Gas: Canaccord Genuity moves target price from 180p to 190p keeping its buy recommendation.Fastnet Oil & Gas: Cantor Fitzgerald initiates with a target price of 28p and a buy recommendation.Gem Diamonds: RBC Capital moves target price from 180p to 190p keeping its neutral rating.GlaxoSmithKline: Jefferies cuts target price from 1650p to 1600p and maintains a hold recommendation.Greencore: Investec ups target price from 265p to 285p and reiterates a buy recommendation. Panmure Gordon takes target price from 275p to 292p and maintains a buy recommendation.G4S: Credit Suisse cuts target price from 275p to 245p and retains a neutral rating.Heritage Oil: Canaccord Genuity raises target price from 280p to 355p reiterating its buy recommendation.HSBC Holdings: Credit Suisse reduces target price from 780p to 580p downgrading from outperform to underperform.ICAP: Credit Suisse cuts target price from 415p to 395p and reiterates an underperform rating.Prudential: Credit Suisse raises target price from 1500p to 1600p and leaves its outperform rating unchanged.Resolution: Canaccord Genuity downgrades from buy to hold with a target price of 375p.Royal Bank of Scotland: Espirito Santo cuts target price fro 365p to 320p and maintains a neutral rating.Royal Dutch Shell: RBC Capital takes target price from 2520p to 2600p and retains an outperform rating.Sainsbury: Nomura cuts target price from 370p to 320p keeping a neutral rating.Smiths Group: Investec places its target price (prev.: 1550p) under review maintaining a buy recommendation.Speedy Hire: RBC Capital moves target price from 51p to 62p maintaining its neutral rating.Versarien: Westhouse Securities shifts target price from 30p to 35p and keeps a buy recommendation.Xaar: FinnCap downgrades from buy to hold with a target price of 900p. Investec reduces target price from 1180p to 960p and retains an add rating.
More News
11 Apr 2016 15:04

AGM, EGM Calendar - Week Ahead

Read more
31 Mar 2016 09:33

WINNERS & LOSERS SUMMARY: AO World Surges On Strong Fourth Quarter

Read more
31 Mar 2016 09:21

Orphan drug specialist Amryt Pharma to reverse into AIM's Fastnet

(ShareCast News) - Headed by Shire founder Harry Stratford as its chairman, speciality drug company Amryt Pharmaceuticals has confirmed its plan to reverse into AIM-listed Fastnet, raise £10m and acquire two drug developing businesses. Following a capital reorganisation planned for 18 April, the rev

Read more
31 Mar 2016 07:41

Fastnet Equity To Become Amryt Pharma After Reverse Takeover (ALLISS)

Read more
22 Feb 2016 10:33

CORRECT: Fastnet In Talks For Reverse Takeover Of Amryt Pharma (ALLISS)

Read more
22 Feb 2016 08:56

Fastnet Equity In Talks For Reverse Takeover Of Amryt Pharma (ALLISS)

Read more
22 Feb 2016 08:42

Fastnet Equity in talks to acquire Amryt Pharmaceuticals  

(ShareCast News) - Fastnet Equity shares have been suspended from trading after it said it is in advanced discussions for a reverse takeover of Amryt Pharmaceuticals. The AIM-listed company said on Monday if the acquisition proceeds, the enlarged group will become a late stage, specialty biopharmace

Read more
21 Dec 2015 14:20

Fastnet Equity Names Shire Founder Harry Stratford To Board

Read more
18 Dec 2015 11:41

Fastnet Spins Off Energy Assets As It Transitions Into Healthcare

Read more
23 Sep 2015 15:06

AGM, EGM Calendar - Week Ahead

Read more
4 Sep 2015 08:39

Fastnet Eyes Healthcare Industry Investment Opportunities

Read more
28 Aug 2015 07:15

LONDON BRIEFING: Tesla Deal Electrifies Rare Earth And Bacanora Shares

Read more
28 Aug 2015 05:32

AGM, EGM Calendar - Week Ahead

Read more
27 Aug 2015 15:27

AGM, EGM Calendar - Week Ahead

Read more
27 Aug 2015 05:15

AGM, EGM Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.